 | |
| Company type | Public |
|---|---|
| Nasdaq: MDVN | |
| Industry | Pharmaceutical industry |
| Founded | 2004 |
| Defunct | 2016 |
| Fate | Acquired by Pfizer |
| Headquarters | San Francisco, California , United States |
Key people | David Hung & Steve Gorlin |
| Website | medivation.com |
| Footnotes / references [1][2] | |
Medivation, Inc. was an American biopharmaceutical company focused on development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation was headquartered in San Francisco, California, beginning operations in December 2004 with the acquisition of Medivation Neurology, Inc.[3] Its final CEO was David Hung.[4]
Medivation, in collaboration with Astellas, was in development of enzalutamide for multiple stages of prostate cancer and for breast cancer. On August 31, 2012, Medivation and Astellas announced that the U.S. Food and Drug Administration (FDA) granted approval to XTANDI (enzalutamide) capsules for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI is an oral, once-daily androgen receptor inhibitor.[5]
Pfizer announced it would acquire the company in August 2016 for $14 billion and completed the acquisition in October 2016.[6]
- ^ "FORM 10-K".
- ^ "Securities registration termination [Section 12(b)]".
- ^ "Investor relations". Medivation. Archived from the original on 3 July 2007. Retrieved 17 November 2012.
- ^ "Management team". Medivation. Retrieved 17 November 2012.
- ^ "Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Medivation, Inc". Law Offices of Howard G. Smith. 2010-03-03. Archived from the original on 10 August 2014. Retrieved 17 November 2012.
- ^ "Pfizer Completes Acquisition of Medivation". Yahoo! Finance. Retrieved 4 January 2017.